Tom 4, Nr 4 (2019)
Artykuł przeglądowy
Opublikowany online: 2020-01-29

dostęp otwarty

Wyświetlenia strony 1187
Wyświetlenia/pobrania artykułu 1239
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Chlorek dekwaliniowy – atrakcyjna opcja terapeutyczna w leczeniu zakażeń pochwy

Krzysztof Drews1, Anna Romała1
Ginekologia i Perinatologia Praktyczna 2019;4(4):155-159.

Streszczenie

Zakażenia pochwy są jedną z najczęstszych przyczyn wizyt w gabinetach ginekologicznych. Zaburzenia fizjologicznej
flory bakteryjnej pochwy prowadzą do rozwoju infekcji, których występowanie wiąże się z możliwością rozwoju
poważnych powikłań. Istotnymi problemami w codziennej praktyce są występowanie oporności na standardowe
leczenie oraz częste nawroty choroby. W pracy przedstawiono aktualny stan wiedzy oraz wytyczne dotyczące skuteczności
terapeutycznej i zastosowania w praktyce klinicznej chlorku dekwalinianu.

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Fettweis JM, Brooks JP, Serrano MG, et al. Differences in vaginal microbiome in African American women versus women of European ancestry. Microbiology. 2014; 160(Pt 10): 2272–2282.
  2. Ma B, Forney LJ, Ravel J. Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol. 2012; 66: 371–389.
  3. Badger J, Ng P, Venter J. The Human Genome, Microbiomes, and Disease. Metagenomics of the Human Body. 2010: 1–14.
  4. Sieroszewski P, Bober Ł, Kłosiński W. Zakażenia podczas ciąży. Perinat Neonatol Ginekol. 2012; 5: 65–84.
  5. Donders GGG. Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol. 2007; 21(3): 355–373.
  6. Mårdh PA, Rodrigues AG, Genç M, et al. Facts and myths on recurrent vulvovaginal candidosis--a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS. 2002; 13(8): 522–539.
  7. Romanik M, Ekiel A, Tomana L, et al. Waginoza bakteryjna - problemy w terapii. Wiadomości Lekarskie. 2007; 60: 64–67.
  8. Han C, Li H, Han L, et al. Aerobic vaginitis in late pregnancy and outcomes of pregnancy. Eur J Clin Microbiol Infect Dis. 2019; 38(2): 233–239.
  9. Karasz A, Anderson M. The vaginitis monologues: women's experiences of vaginal complaints in a primary care setting. Soc Sci Med. 2003; 56(5): 1013–1021.
  10. Bilardi JE, Walker S, Temple-Smith M, et al. The burden of bacterial vaginosis: women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One. 2013; 8(9): e74378.
  11. Palmeira-de-Oliveira R, Palmeira-de-Oliveira A, Martinez-de-Oliveira J. New strategies for local treatment of vaginal infections. Adv Drug Deliv Rev. 2015; 92: 105–122.
  12. Wielgoś M, Pietrzak B. Bacterial vaginosis: diagnosis and treatment. Menopausal Review. 2012; 5: 356–363.
  13. Sobel J. Bacterial Vaginosis. Annual Review of Medicine. 2000; 51(1): 349–356.
  14. Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 1985; 152(7 Pt 2): 924–935.
  15. Cook RL, Downs JS, Marrazzo J, et al. Preferred characteristics of vaginal microbicides in women with bacterial vaginosis. J Womens Health (Larchmt). 2009; 18(8): 1163–1167.
  16. Biggs W, Williams R. Common Gynecologic Infections. Primary Care: Clinics in Office Practice. 2009; 36(1): 33–51.
  17. Forsum U, Holst E, Larsson PG, et al. Bacterial vaginosis--a microbiological and immunological enigma. APMIS. 2005; 113(2): 81–90.
  18. Goldstein EJ, Citron DM, Cherubin CE, et al. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. J Antimicrob Chemother. 1993; 31(3): 363–372.
  19. Goldstein EJC, Citron DM, Merriam CV, et al. In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis. Antimicrob Agents Chemother. 2002; 46(12): 3995–3996.
  20. Srinivasan S, Fredricks DN. The human vaginal bacterial biota and bacterial vaginosis. Interdiscip Perspect Infect Dis. 2008; 2008: 750479.
  21. Polatti F. Bacterial vaginosis, Atopobium vaginae and nifuratel. Curr Clin Pharmacol. 2012; 7(1): 36–40.
  22. Sobel J. Vulvovaginal candidosis. The Lancet. 2007; 369(9577): 1961–1971.
  23. Tietz HJ. Therapy problems in chronic recurrent vaginal mycosis. Ther Umsch. 2002; 59(9): 481–484.
  24. Cleveland A. Vaginitis: finding the cause prevents treatment failure. Cleve Clin J Med. 2000; 67(9): 634, 637–642, 645.
  25. Marrazzo J. Vulvovaginal candidiasis. BMJ. 2003; 326(7397): 993–994.
  26. Sherrard J, Wilson J, Donders G, et al. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018; 29(13): 1258–1272.
  27. D’Auria F, Simonetti G, Strippoli V. Caratteristiche antimicrobiche di una tintura al dequalinio cloruro. Ann Ig. 1989; 1: 1227–1241.
  28. Della Casa V, Noll H, Gonser S, et al. Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittelforschung. 2002; 52(9): 699–705.
  29. Tischer M, Pradel G, Ohlsen K, et al. Quaternary ammonium salts and their antimicrobial potential: targets or nonspecific interactions? ChemMedChem. 2012; 7(1): 22–31.
  30. Block SS. Disinfection, Sterilization, and Preservation. Soil Science. 1977; 124(6): 378.
  31. Hugo WB, Frier M. Mode of action of the antibacterial compound dequalinium acetate. Appl Microbiol. 1969; 17(1): 118–127.
  32. Lopes dos Santos Santiago G, Grob P, Verstraelen H, et al. Susceptibility testing of Atopobium vaginae for dequalinium chloride. BMC Res Notes. 2012; 5: 151.
  33. Mendling W, Palmeira-de-Oliveira A, Biber S, et al. An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. Arch Gynecol Obstet. 2019; 300(1): 1–6.
  34. Turner RJ, Taylor DE, Weiner JH. Expression of Escherichia coli TehA gives resistance to antiseptics and disinfectants similar to that conferred by multidrug resistance efflux pumps. Antimicrob Agents Chemother. 1997; 41(2): 440–444.
  35. Ali-Melkkilä T, Kaila T, Kanto J. Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. Acta Anaesthesiol Scand. 1989; 33(6): 513–517.
  36. Liebmann B, Henke D, Spahn-Langguth H, et al. Determination of the quaternary compound ciclotropium in human biological material after hydrolysis and derivatization with the fluorophor flunoxaprofen chloride. J Chromatogr. 1991; 572(1-2): 181–193.
  37. Schladitz-Keil G, Spahn H, Mutschler E. Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data. Arzneimittelforschung. 1986; 36(6): 984–987.
  38. Petersen E, Weissenbacher E, Hengst P, et al. Local Treatment of Vaginal Infections of Varying Etiology with Dequalinium Chloride or Povidone Iodine. Arzneimittelforschung. 2011; 52(09): 706–715.
  39. Weissenbacher ER, Donders G, Unzeitig V, et al. Fluomizin Study Group. A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest. 2012; 73(1): 8–15.
  40. Strecker M, Kokemohr H, Teucher T, et al. Antiseptika gegen vulvovaginitiden. TW Gynäkologie. 1993; 6: 409–412.
  41. Radzinsky V, Ordiyants I, Chetvertakova E, et al. Two Stage therapy for Vaginal Infections. Akusherstvo i Ginekologiia. 2011; 5: 78–81.
  42. Mendling W, Martius J, Hoyme U. S1-Guideline on Bacterial Vaginosis in Gynecology and Obstetrics. Geburtshilfe und Frauenheilkunde. 2014; 74(01): 51–54.
  43. SPG - Sociedade Portuguesa De Ginecologia. http://www.spginecologia.pt.
  44. http://www.somersetccg.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=6573.
  45. https://www.scottishmedicines.org.uk/media/1551/dequalinium_fluomizin_final_oct_2016_amended_311016_for_website.pdf..
  46. All Wales Medicines Strategy Group. The Pharmaceutical Journal. 2014.
  47. Guía Práctica de Asistencia S.E.G.O: Diagnóstico y tratamiento de las infecciones vulvovaginales Actualizado 2018. Madrid. Sociedad Española de Obstetricia y Ginecología. Enero 2018 Tratamientos actualizados y consensuados para las Infecciones de Transmisión Sexual.
  48. Mendling W, Weissenbacher ER, Gerber S, et al. Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review. Arch Gynecol Obstet. 2016; 293(3): 469–484.
  49. Dankovich D, Gopchuk E. New opportunities in preparation of women with reproductive tracts microbiocenosis disorder for gynaecologic intervention. Women’s Health. 2006; 2(26): 1–4.
  50. Charakterystyka produktu leczniczego Fluomizin.
  51. Hijona JJ, Carballo AL, Sánchez MS, et al. Vaginal antiseptics reduce the risk of perinatal infection with group B streptococci. J Matern Fetal Neonatal Med. 2019; 32(16): 2741–2745.



Ginekologia i Perinatologia Praktyczna